~~<i id='8447CCCD28'><strike id='8447CCCD28'><tt id='8447CCCD28'><pre id='8447CCCD28'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：explore 2025-09-28 00:51:58 - browse：242

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： SNAP should offer more nutrition education

hotspot

leisure time

focus

hotspot

explore

entertainment

AdobeAllAmericansareworriedaboutinflation.Thepricesforhousing,clothesandfoodatthesupermarketareeyepo

WSS

Why health care costs have stayed mostly flat since 2010

Christmas in the PICU brings some surprising joy

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Trump cancels press conference intended to dispute Georgia election interference charges

New definition of a human embryo proposed amid rapid advances

knowledge

comprehensive

hotspot

Jerome Adams on the need for new antivirals for Covid

The pain doctors face in trying to build their families

How one medical school became remarkably diverse

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Affirmative action in medical school literally saved lives

SEC charges former device maker CEO with $41 million fraud

Walensky prepares to leave CDC — and Congress — behind

CRISPR gene editing developments we’re watching in 2024

How one medical school became remarkably diverse

Medicare Advantage beneficiaries sue Humana over algorithm use

leisure time

New definition of a human embryo proposed amid rapid advances

As Maui death toll rises, number of missing remains unclear

Evacuations in place as 3 wildfires burn in eastern Washington state

HCA sued by state AG for quality issues at Mission Health

New details revealed about Purdue's marketing of OxyContin

Listen: Racing for gene therapy & a pioneering approval

focus

hotspot

explore

entertainment